Final report of the Expert Scientific Group (ESG) which was set up following the very serious adverse reactions that occurred in the first-in-man clinical trial of TGN412 in March 2006. The trial was performed in a private clinical research unit at Northwick Park. This report was an independent report to the Secretary of State for Health.
1. Executive Summary
2. Introduction
3. Background to the TGN1412 incident as at July 2006
Prepared by the Secretariat to the ESG
A Pre-clinical development of TGN1412
B Transition to Clinical Development of TGN1412
C Phase One Clinical Trial and Adverse Events at Northwick Park Hospital
D MHRA GCP, GMP and GLP Investigations
4. Paper published in the New England Journal of Medicine
5. NIBSC Special Cytokine Study and Follow Up Studies
6. Summary of Stakeholder Consultations
7. Predicting Hazards in Pre-clinical to Clinical Transition
8. Risk Reduction and Risk Management
9. Scope and Summary of the Recommendations
10. Appendices
Contact details for obtaining hard-copy DH publications.

Useful tips to ensure you get the most from PDFs and the free Reader program. Topics covered include accessibility, troubleshooting and searching files.